Sulfonylureas cause hypoglycemia by which of the following mechanisms?

Explanation

## Sulfonylureas: Mechanism of Action and Hypoglycemia Risk **Key Point:** Sulfonylureas act by blocking ATP-sensitive potassium (K-ATP) channels on pancreatic β-cells, causing membrane depolarization and triggering insulin secretion regardless of blood glucose levels. This glucose-independent mechanism is why they carry a significant hypoglycemia risk. ### Mechanism of Hypoglycemia 1. **K-ATP Channel Blockade:** Sulfonylureas bind to and block ATP-sensitive potassium channels on the β-cell membrane 2. **Membrane Depolarization:** Blocking K-ATP channels prevents potassium efflux, causing depolarization 3. **Calcium Influx:** Depolarization opens voltage-gated calcium channels 4. **Insulin Secretion:** Increased intracellular calcium triggers exocytosis of insulin granules 5. **Glucose-Independent Release:** Insulin is secreted even when blood glucose is low → hypoglycemia **High-Yield:** The glucose-independent nature of sulfonylurea-induced insulin secretion is the key reason they cause hypoglycemia, especially in fasting states or with missed meals. ### Sulfonylurea Generations and Characteristics | Generation | Examples | Potency | Duration | Notes | |------------|----------|---------|----------|-------| | **First** | Tolbutamide, Chlorpropamide | Lower | Long (24-72 hrs) | Older agents, more side effects | | **Second** | Glibenclmide, Gliclazide, Glipizide | Higher | Intermediate (12-24 hrs) | More commonly used | | **Third** | Glimepiride | Highest | Long (24 hrs) | Selective for β-cell K-ATP channels | **Mnemonic:** **SULF** = **S**timulates **U**nconditional **L**ate **F**asting insulin (glucose-independent) ### Clinical Pearl **Warning:** Sulfonylureas are contraindicated in: - Type 1 diabetes (β-cell destruction) - Brittle diabetes (unpredictable hypoglycemia) - Pregnancy (teratogenic risk) - Patients with severe hepatic or renal disease - Sulfonamide allergy (cross-reactivity possible) ### Why Hypoglycemia Occurs with Sulfonylureas Unlike incretin-based agents (DPP-4 inhibitors, GLP-1 agonists) that suppress insulin secretion when glucose is low, sulfonylureas continue to stimulate insulin release regardless of blood glucose status. This makes them the **highest-risk class for hypoglycemia** among oral hypoglycemics.